A phase II study of CAM2043 for treatment of pulmonary hypertension
Latest Information Update: 16 May 2019
Price :
$35 *
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension; Systemic scleroderma
- Focus Proof of concept; Therapeutic Use
- 09 May 2019 According to a Camurus media release, the company plans to initiate this study in patients by the end of the 2019.
- 08 Feb 2019 Planned initiation date changed to 1 Jul 2019.
- 08 Feb 2019 New trial record